The catalytic subunit p110δ of phosphoinositide 3-kinase (PI3K) encoded by PIK3CD has been implicated in some human solid tumors. However, its roles in colorectal cancer (CRC) remain largely unknown. Here we found that PIK3CD was overexpressed in colon cancer tissues and CRC cell lines and was an independent predictor for overall survival (OS) of patients with colon cancer. The ectopic overexpression of PIK3CD significantly promoted CRC cell growth, migration and invasion in vitro and tumor growth in vivo. In contrast, inhibition of PIK3CD by specific small-interfering RNA or idelalisib dramatically suppressed CRC cell growth, migration and invasion in vitro and tumor growth in vivo. Moreover, PIK3CD overexpression increased AKT activity, nuclear translocation of β-catenin and T-cell factor/lymphoid enhancer factor (TCF/LEF) transcriptional activity and decreased glycogen synthase kinase 3β (GSK-3β) activity, whereas PIK3CD inhibition exhibited the opposite effects.
the molecular mechanisms underlying CRC progression might help identify novel therapeutic targets and consequently improve its Class IA PI3K comprise a p110 catalytic subunit and a p85 regulatory subunit. Class IA catalytic isoforms, p110α, p110β and p110δ, are encoded by genes PIK3CA, PIK3CB and PIK3CD, respectively.
Accumulated evidence has demonstrated that p110 isoforms play critical roles in cell proliferation, migration and survival. 3, 4, [6] [7] [8] is frequently mutated in human cancers, but mutations in other class IA catalytic isoforms are rare. 3, 4 However, PIK3CB and PIK3CD are generally overexpressed or amplified in cancers. 4 PIK3CD is primarily expressed in leukocytes and plays a critical role in some hematological malignancies. 3, 4, 9 Furthermore, PIK3CD has recently been implicated in some human solid tumors, including hepatocellular carcinoma, glioma, glioblastoma, neuroblastoma and breast cancer. [10] [11] [12] [13] [14] However, little is known about the roles and underlying molecular mechanisms of PIK3CD in CRC.
In this study, we found that PIK3CD was overexpressed and an independent prognostic factor in colon cancer patients. Furthermore, our results demonstrated that PIK3CD induced cell growth and invasion by the activating AKT/GSK-3β/β-catenin pathway in CRC.
| MATERIAL S AND ME THODS

| Human tissue specimens
The present study included 153 patients who underwent surgery for colon cancer in the First Affiliated Hospital of Guangzhou Medical University (Guangzhou, China) from January 2009 to December 2011. None of these patients had received chemotherapy or radiotherapy before surgery. Colon cancer and matched adjacent normal tissue specimens (not less than 2 cm away from the cancer) were obtained from all patients after resection and embedded in paraffin. All specimens were histopathologically confirmed. All patients were staged according to the 7th edition of the American Joint Committee on Cancer (AJCC) TNM staging system.
These patients were followed after surgery until April 2017, with a median follow up of 66 months (range, 1-91 months). In addition,
8 surgical specimens (both tumor and adjacent normal tissue) from colon cancer patients were collected immediately after surgery and stored at −80°C for later RNA and protein extraction. Informed consent was obtained from all patients before surgery. The present study was approved by the Ethics Committees of our institute.
| Cell culture
Normal human colon epithelial cell line (NCM460) and human CRC   cell lines (HT-29, HCT-15, LoVo, SW480, DLD-1, HCT-8 and HCT-116) were maintained in DMEM (Gibco, Grand Island, NY, USA) supplemented with 10% FBS (Hyclone, USA) and 1% penicillin/streptomycin in a humidified incubator with 5% CO 2 at 37°C.
| Real-time PCR
Total RNA was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The complementary DNA was synthesized and real-time PCR was performed as described previously. [15] [16] [17] [18] The primers for human PIK3CD (forward primer: 5′-CATATGTGCTGGGCATTGGC-3′, reverse primer: 5′-TTTCA CAGTAGCCCCGGAAC-3′), β-catenin (forward primer: 5′-AACTTGC CACACGTGCAATC-3′, reverse primer: 5′-AGGTTATGCAAGGT CCCAGC-3′) and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (forward primer: 5′-GAGTCAACGGATTTGGTCGT-3′, reverse primer: 5′-GACAAGCTTCCCGTTCTCAG-3′) were used for the real-time PCR. The amplification reactions were performed under the following conditions: 1 cycle at 95°C for 3 minutes, followed by 40 cycles at 95°C for 15 seconds, and 60°C for 30 seconds.
| Western blot
Western blot was performed as previously described. [16] [17] [18] Cytoplasmic and nuclear protein fractions were extracted from cells 
| Immunohistochemistry
Immunohistochemistry was performed on the 4 μm-thick paraffinembedded tissue sections as previously described. [15] [16] [17] [18] 
| Lentivirus production and transduction
PIK3CD-overexpressing lentivirus was generated and infected as described previously. 17 In brief, the PIK3CD sequences were amplified and cloned into the pLV3 vector (GeneChem, Shanghai, China). Subsequently, the lentiviral plasmids were transfected into HEK293T cells and the lentivirus-containing medium was collected.
Then, CRC cells infected with the viral supernatant were selected to obtain cells stably expressing the constructs.
| Small interfering RNA transfection
The sense strand sequences of small interfering RNA (siRNA) 5-diphenyltetrazoliumbromide (MTT) assay and cell motility was measured using a wound healing assay, as previously described. [16] [17] [18] Cell migration and invasion assays were performed using Transwell chambers (Costar; Corning) without or with coated Matrigel (BD Biosciences, San Jose, CA, USA), as previously described.
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| Colony formation assay
Cells (4 × 10 2 ) were plated into 6-well plates with DMEM with 10% FBS. After 2 weeks of culture, the cells were fixed with 4% formaldehyde and stained with 0.5% crystal violet. The number of colonies (>50 cells/colony) was counted under a microscope. 
| Luciferase reporter assay
| Statistical analysis
Statistical analyses were carried out using SPSS 13.0 software (SPSS, Chicago, IL, USA). The association between PIK3CD or β-catenin expression and clinicopathological parameters was evaluated using the χ 2 test or Fisher's exact test. The correlation between the PIK3CD expression and β-catenin expression in colon cancer patients was determined using the Spearman correlation test. Survival curves were plotted using the Kaplan-Meier method and compared by log-rank test. Multivariate analysis was performed using the Cox proportional hazard model. Data for continuous variables were presented as mean ± SD and differences between groups were compared using ANOVA or Student's t test.
P ≤ .05 was considered statistically significant.
| RE SULTS
| Overexpression of PIK3CD was significantly correlated with distant metastasis and poor prognosis in human colon cancer
We first examined PIK3CD expression in human colon epithelial cell . The intensity of bands was quantified using ImageJ software and normalized to GAPDH (Right). E, Representative immunostaining of PIK3CD in adjacent normal tissues (Normal), colon cancer (Cancer) tissues without or with distant metastasis (×200 magnification). F, Kaplan-Meier analysis of the correlation between PIK3CD and overall survival of 153 colon cancer patients. P-value is based on a log-rank test expression levels were significantly upregulated in CRC cell lines compared with NCM460 cells (Figure 1A,B) . Moreover, PIK3CD
mRNA and protein expression levels in colon cancer tissues were higher than those in the matched adjacent normal tissues (P < .01)
To further validate the relationship between PIK3CD expression and human colon cancer, we analyzed PIK3CD expression in 153 pairs of colon cancer and adjacent normal tissues by immunohistochemistry. The representative immunostaining profile of PIK3CD is shown in Figure 1E . PIK3CD positivity was detected in 40.52% (62/153) of the colon cancer specimens, whereas it was detected in 7.4% (12/153) of matched adjacent normal tissues (P < .001). Furthermore, PIK3CD
overexpression was significantly associated with distant metastasis, higher TNM stage, CEA ≥ 5 ng/mL and higher proliferation index (Ki-67 label index ≥ 50%) ( Figure 1E ). Kaplan-Meier analyses showed that colon cancer patients with higher levels of PIK3CD had poorer overall survival (OS) (P < .001; Figure 1F ). Univariate and multivariate analyses revealed that PIK3CD was an independent predictor for OS of patients with colon cancer (Table S1 and Table 2 ). These data indicate that overexpression of PIK3CD correlates with advanced TNM stage and distant metastasis and that PIK3CD might be a potential biomarker for unfavorable prognosis in patients with colon cancer.
| PIK3CD induced colorectal cancer cell growth, migration and invasion
To explore the biological functions of PIK3CD in CRC cells, we carried out in vitro gain-of-function analyses using HCT-15 cells that stably overexpressed PIK3CD. We found that the PIK3CD mRNA and protein levels were dramatically increased in HCT- 
| Inhibition of PIK3CD suppressed colorectal cancer cell growth, migration and invasion
To further confirm the effects of PIK3CD on CRC cell behavior, we inhibited PIK3CD in HCT-116 cells using siRNA targeting PIK3CD 
| PIK3CD promoted cell growth, migration and invasion by activating β-catenin signaling in colorectal cancer cells
Wnt/β-catenin signaling pathway is frequently activated and is critical for tumor initiation and progression in CRC, 23 ,24 therefore, we examined whether PIK3CD activates Wnt/β-catenin signaling.
Western blot analyses showed that overexpression of PIK3CD 
| PIK3CD mediated cell growth, migration, invasion and β-catenin signaling activation through regulating AKT/GSK-3β pathway in colorectal cancer cells
To further elucidate the mechanism of PIK3CD-mediated activation of β-catenin signaling, we investigated the status of GSK3β, a negative regulator of β-catenin signaling and a downstream target of PI3K/AKT signaling. 25, 26 Our results showed that overexpression of PIK3CD significantly upregulated, whereas knockdown of PIK3CD downregulated, AKT phosphorylation at the Ser473 site (active AKT) and GSK-3β phosphorylation at the Ser9 site (inactive GSK-3β) levels ( Figure 5A ). However, neither PIK3CD overexpression nor PIK3CD knockdown altered the total levels of AKT or GSK3β ( Figure 5A ). These findings indicate that PIK3CD enhances AKT activity, and further suppresses GSK-3β activity via the increment of GSK-3β phosphorylation at Ser9 site in CRC cells. 
| PIK3CD promoted colorectal cancer growth and β-catenin signaling activation in vivo
Given that in vitro experiments demonstrated that PIK3CD promoted CRC cell growth, we next determined whether PIK3CD
could promote CRC growth in vivo. We found that the average volume and weight of tumors derived from HCT-15 cells overexpressing PIK3CD were dramatically larger than those of control in nude mice ( Figure 6A-C) . We further investigated the effects of PIK3CD inhibition on CRC growth in vivo. Expectedly, inhibition of PIK3CD F I G U R E 4 PIK3CD induces colorectal cancer (CRC) cell growth, migration and invasion by activating β-catenin signaling. A, Effect of PIK3CD overexpression or inhibition on β-catenin, phosphorylated β-catenin (Ser33/37/Thr41) (p-β-catenin), Cyclin D1 and C-myc protein expression in CRC cells. B, Cytoplasmic and nuclear fractions of both β-catenin and p-β-catenin expressions in indicated cells in response to PIK3CD overexpression or suppression. Histone 3 was used as a nuclear loading control. C, TCF/LEF transcriptional activity was examined by dual-luciferase assays in indicated cells in response to PIK3CD overexpression or inhibition. D, After HCT-15 cells overexpressing PIK3CD were transfected with 100 nmol/L indicated siRNA or NC for 48 h, β-catenin mRNA and protein expression was determined by real-time PCR (left) and western blot (right), respectively. After HCT-15 cells overexpressing PIK3CD (HCT-15-PIK3CD) were transfected with 100 nmol/L β-catenin siRNA-2 or NC for 48 h. E, TCF/LEF transcriptional activity was analyzed in indicated cells. F, The protein levels of β-catenin, p-β-catenin, Cyclin D1 and C-myc in indicated cells were assessed by western blot analysis. G, Cell growth of indicated cells was evaluated by MTT assays. H, Migratory and invasive potential of indicated cells, as determined by Transwell assays. H, ×100 magnification.*P < .05; **P < .01. NC, negative control by idelalisib markedly suppressed growth of CRC xenograft tumors in nude mice ( Figure 6D-F) . These results reveal that PIK3CD promotes the tumorigenesis and development of CRC in vivo.
Furthermore, we examined the expression of β-catenin, phosphorylated β-catenin, C-myc and CyclinD1 in the harvested tumor tissues by immunohistochemistry staining. The results showed that F I G U R E 5 AKT/GSK-3β signaling is crucial for PIK3CD-induced cell growth, invasion and β-catenin signaling activation in colorectal cancer (CRC) cells. A, Western blot analysis of AKT, phosphorylated AKT (Ser473) (p-AKT) (active AKT), GSK-3β and phosphorylated GSK-3β (Ser9) (p-GSK-3β) (inactive GSK-3β) in indicated cells. After HCT-15 cells overexpressing PIK3CD were treated with 10 μmol/L MK-2206 for 24 h. B, TCF/LEF transcriptional activity was analyzed in indicated cells. C, The protein levels of AKT, p-AKT, GSK-3β, p-GSK-3β, β-catenin, p-β-catenin, Cyclin D1 and C-myc in indicated cells were assessed by western blot analysis. D, The cells were incubated for another 24 h, cell viability of indicated cells was evaluated by MTT assays. E, Quantification of indicated migrating or invading cells. E, ×100 magnification. *P < .05; **P < .01 Figure 6G ). Collectively, our data suggest that PIK3CD can promote CRC growth and β-catenin signaling activation in vivo, which is consistent with our in vitro results.
| PIK3CD was positively correlated with β-catenin abnormal expression in human colon cancer samples
To further investigate the correlation between PIK3CD and β-catenin in colon cancer, we detected β-catenin expression using immunohistochemistry in the same cohort of colon cancer samples used to assess the expression levels of PIK3CD. The results demonstrated that β-catenin abnormal expression was significantly higher in colon cancer tissues than that in matched normal tissues (59.5% vs 7.2%, P < .001; Figure 7A ). Moreover, β-catenin abnormal expression was closely correlated with distant metastasis, higher TNM stage, CEA ≥ 5 ng/mL and higher proliferation index (Table S2) . Kaplan-Meier analyses demonstrated that β-catenin abnormal expression predicted poorer OS (P < .001; showed β-catenin abnormal expression in negative staining of the PIK3CD group (P < .01) ( Figure 7C ). Thus, there was a significant positive correlation between PIK3CD expression and β-catenin abnormal expression in these colon cancer samples (r = .546, P < .001). Taken together, these data support that PIK3CD regulates β-catenin activation in human colon cancer tissues.
| D ISCUSS I ON
In this study, we demonstrated that the catalytic subunit p110δ of PI3K (PIK3CD) was overexpressed in colon cancer samples and a variety of human CRC cell lines and that PIK3CD was an independent predictor for OS of patients with colon cancer. Moreover, the ectopic expression of PIK3CD significantly promoted CRC cell growth, migration and invasion in vitro and tumor growth in vivo.
In contrast, suppression of PIK3CD dramatically impaired CRC cell growth, migration and invasion in vitro and tumor growth in vivo. Therefore, these data suggest that PIK3CD plays an essential, nonredundant role in CRC progression and that PIK3CD might be a novel potential therapeutic target for CRC.
Inactivation of p110δ can break tumor-induced immune tolerance and, thus, block progression of several hematological and solid cancers. 27 Idelalisib (also known as GS-1101 and CAL-101), the p110δ-selective inhibitor, has shown impressive therapeutic efficacy in human chronic lymphocytic leukemia and indolent lymphoma. 28, 29 Previous studies have shown that inactivation of p110δ can suppress neuroblastoma cell and breast tumor growth and metastasis. 13, 30 Our results revealed that PIK3CD inhibition by idelalisib or specific siRNA remarkably impaired CRC cell growth, migration and invasion, suggesting that inhibition of PIK3CD might be a promising treatment option for CRC. Our findings provide a rationale for the use of idelalisib in the treatment of CRC.
The Wnt/β-catenin signaling pathway plays a pivotal role in normal embryonic development, adult tissue homeostasis and regulating various cellular processes, including cell differentiation, proliferation and apoptosis. [31] [32] [33] Dysregulation of Wnt/β-catenin signaling has been widely implicated in cancer. [31] [32] [33] [34] and GSK-3β. Thereafter, the stabilized β-catenin accumulates in the cytoplasm and translocates to the nucleus, where it interacts with TCF/LEF transcription factors to transactivate target genes, such as C-myc and CyclinD1. [31] [32] [33] However, in the absence of Wnt ligands, cytoplasmic β-catenin is phosphorylated at specific serine and threonine residues by CK1 and GSK-3β in the destruction complex and is subsequently degraded by the ubiquitin-proteasome system, keeping levels of cytoplasmic and nuclear β-catenin low. [31] [32] [33] We found that PIK3CD overexpression dramatically increased cytoplasmic accumulation and nuclear translocation of β-catenin and the transactivating activity of β-catenin in CRC cells, but decreased phosphorylated β-catenin levels. However, the inhibition of PIK3CD exerted the opposite effect. Furthermore, blocking β-catenin signaling abrogated the stimulatory effect of PIK3CD on cell growth, migration and invasion. In addition, PIK3CD expression positively correlated with β-catenin abnormal expression in the colon cancer samples. Therefore, these findings suggest that PIK3CD promotes CRC cell growth through activating β-catenin signaling.
GSK-3β can phosphorylate β-catenin at Ser33/37/Thr41 residues, resulting in β-catenin sequestration and degradation. 37, 38 Therefore, GSK-3β is a negative regulator of β-catenin.
Accumulated evidence has shown that GSK-3β is a downstream target of the PI3K/AKT pathway and could be inactivated by AKTmediated phosphorylation at its Ser 9 residue. 25, 39, 40 Our results demonstrated that PIK3CD overexpression significantly upregulated, whereas inhibition of PIK3CD markedly downregulated, phosphorylated (activated) AKT and phosphorylated (inactivated)
GSK-3β levels. Furthermore, blockade of PI3K/AKT pathway reversed the ability of PIK3CD to induce GSK-3β inactivation, β-catenin pathway activation, cell growth, migration and invasion.
Therefore, these data reveal that PIK3CD-mediated AKT activation leads to inactivation of GSK-3β and consequent β-catenin pathway activation by reducing phosphorylation of β-catenin at Ser33/37/Thr41.
In conclusion, our results reveal that PIK3CD is upregulated and is an independent prognostic factor in CRC and that PIK3CD
induces CRC cell growth, migration and invasion by activating AKT/GSK-3β/β-catenin signaling. Thus, these findings suggest that PIK3CD is a novel independent prognostic biomarker for CRC and that inhibition of PIK3CD might be a promising strategy for CRC.
